Ameriprise
ADPT icon

Ameriprise’s Adaptive Biotechnologies ADPT Stock Holding History

Ameriprise’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.3M Sell
1,087,754
-1,929,587
-64% -$29.6M ﹤0.01% 1431
2026
Q1 		$41.9M Buy
3,017,341
+426,357
+16% +$6.79M 0.01% 964
2025
Q4 		$42.1M Sell
2,590,984
-3,380,722
-57% -$55.2M 0.01% 971
2025
Q3 		$89.3M Buy
5,971,706
+2,731,648
+84% +$33.3M 0.02% 617
2025
Q2 		$37.7M Sell
3,240,058
-3,402,418
-51% -$30.9M 0.01% 1007
2025
Q1 		$49.4M Buy
6,642,476
+5,905,756
+802% +$45.4M 0.01% 845
2024
Q4 		$4.42M Buy
736,720
+654,309
+794% +$3.61M ﹤0.01% 2444
2024
Q3 		$422K Buy
82,411
+31,502
+62% +$137K ﹤0.01% 3543
2024
Q2 		$184K Sell
50,909
-795,470
-94% -$2.52M ﹤0.01% 3703
2024
Q1 		$2.72M Buy
846,379
+791,445
+1,441% +$3.06M ﹤0.01% 2716
2023
Q4 		$269K Sell
54,934
-24,685
-31% -$113K ﹤0.01% 3640
2023
Q3 		$434K Buy
79,619
+27,162
+52% +$180K ﹤0.01% 3459
2023
Q2 		$352K Sell
52,457
-375,507
-88% -$2.79M ﹤0.01% 3567
2023
Q1 		$3.78M Buy
427,964
+59,064
+16% +$521K ﹤0.01% 2505
2022
Q4 		$2.82M Buy
+368,900
New +$2.87M ﹤0.01% 2646
2022
Q2 		– Sell
-648,479
Closed -$9M – 3882
2022
Q1 		$9M Buy
648,479
+68,205
+12% +$1.07M ﹤0.01% 1998
2021
Q4 		$16.3M Sell
580,274
-226
-0% -$6.93K ﹤0.01% 1576
2021
Q3 		$19.7M Buy
580,500
+47,418
+9% +$1.71M 0.01% 1275
2021
Q2 		$21.8M Sell
533,082
-319,950
-38% -$12.4M 0.01% 1283
2021
Q1 		$34.3M Buy
853,032
+97,490
+13% +$5.28M 0.01% 960
2020
Q4 		$44.7M Buy
755,542
+164,134
+28% +$8.46M 0.02% 786
2020
Q3 		$28.8M Buy
591,408
+246,292
+71% +$10.4M 0.01% 888
2020
Q2 		$16.7M Buy
345,116
+12,445
+4% +$454K 0.01% 1167
2020
Q1 		$9.24M Buy
332,671
+45,813
+16% +$1.28M ﹤0.01% 1447
2019
Q4 		$8.58M Buy
286,858
+34,256
+14% +$984K ﹤0.01% 1866
2019
Q3 		$7.81M Buy
252,602
+92,005
+57% +$3.75M ﹤0.01% 1887
2019
Q2 		$7.76M Buy
+160,597
New +$7.11M ﹤0.01% 1918

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Ameriprise's ADPT Position: Q2 2026 in Review

Ameriprise reduced its Adaptive Biotechnologies (ADPT) stake by 64% in Q2 2026, selling an estimated $29.6M and leaving 1,087,754 shares worth $23.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1431.

Ameriprise first reported a position in ADPT in Q2 2019 and has held it in 27 quarters since. The position peaked at $89.3M in Q3 2025. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Ameriprise held 1,087,754 shares of Adaptive Biotechnologies worth $23.3M as of Q2 2026.
  • Ameriprise sold 1,929,587 Adaptive Biotechnologies shares in Q2 2026, an estimated $29.6M.
  • Adaptive Biotechnologies made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #1431 holding.
  • Ameriprise first reported a position in Adaptive Biotechnologies in Q2 2019 and has held it in 27 quarters since.
  • Ameriprise's Adaptive Biotechnologies position peaked at $89.3M in Q3 2025.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.